Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS

Basit Öğe Kaydı
dc.contributor.authorStevens, Kate, I
dc.contributor.authorFrangou, Eleni
dc.contributor.authorIl Shin, Jae
dc.contributor.authorAnders, Hans-Joachim
dc.contributor.authorBruchfeld, Annette
dc.contributor.authorSchoenermarck, Ulf
dc.contributor.authorHauser, Thomas
dc.date.accessioned2024-02-23T14:21:02Z
dc.date.available2024-02-23T14:21:02Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractPatients with immune-mediated kidney diseases are at increased risk of severe coronavirus disease 2019 (COVID-19). The international rollout of COVID-19 vaccines has provided varying degrees of protection and enabled the understanding of vaccine efficacy and safety. The immune response to COVID-19 vaccines is lower in most patients with immune-mediated kidney diseases; either related to immunosuppression or comorbidities and complications caused by the underlying disease. Humoral vaccine response, measured by the presence of antibodies, is impaired or absent in patients receiving rituximab, mycophenolate mofetil (MMF), higher doses of glucocorticoids and likely other immunosuppressants, such as cyclophosphamide. The timing between the use of these agents and administration of vaccines is associated with the level of immune response: with rituximab, vaccine response can only be expected once B cells start to recover and patients with transient discontinuation of MMF mount a humoral response more frequently. The emergence of new COVID-19 variants and waning of vaccine-induced immunity highlight the value of a booster dose and the need to develop mutant-proof vaccines. COVID-19 vaccines are safe, exhibiting a very low risk of de novo or relapsing immune-mediated kidney disease. Population-based studies will determine whether this is causal or coincidental. Such cases respond to standard management, including the use of immunosuppression. The Immunonephrology Working Group and European Vasculitis Society recommend that patients with immune-mediated kidney diseases follow national guidance on vaccination. Booster doses based on antibody measurements could be considered.en_US
dc.identifier.doi10.1093/ndt/gfac052
dc.identifier.endpage1410en_US
dc.identifier.issn0931-0509
dc.identifier.issn1460-2385
dc.identifier.issue8en_US
dc.identifier.pmid35244174en_US
dc.identifier.scopus2-s2.0-85131505857en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1400en_US
dc.identifier.urihttps://doi.org/10.1093/ndt/gfac052
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13419
dc.identifier.volume37en_US
dc.identifier.wosWOS:000804547600001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherOxford Univ Pressen_US
dc.relation.ispartofNephrology Dialysis Transplantationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectIga Nephropathyen_US
dc.subjectImmunologyen_US
dc.subjectImmunosuppressionen_US
dc.subjectRituximaben_US
dc.subjectVasculitisen_US
dc.titlePerspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVASen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu